ArticleCancers2026
Can Contrast-Enhanced Ultrasound Reduce the False-Negative Rate of Metastatic Axillary Lymph Nodes After Neoadjuvant Therapy in Breast Cancer?
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAccurate assessment of axillary lymph node (ALN) status after neoadjuvant therapy (NAT) remains essential for surgical planning in patients with initially node-positive breast cancer. This study evaluated the potential value of contrast-enhanced ultrasound (CEUS) in conjunction with sentinel lymph node biopsy (SLNB) for post-NAT axillary assessment and explored clinicopathologic factors associated with lymph node (LN) status.
methodsIn this retrospective study, 179 patients with cytologically confirmed node-positive breast cancer underwent CEUS after NAT, followed by surgical pathological evaluation. The observed false-negative rate (FNR) of post-NAT CEUS combined with SLNB was compared with that of SLNB alone and post-NAT ultrasound (US) combined with SLNB. Univariable and multivariable generalized estimating equation (GEE) analyses were performed to identify factors associated with LN-level outcomes.
resultsA total of 213 sentinel lymph nodes were analyzed. CEUS combined with SLNB had an observed FNR of 13.25% (95% CI, 7.56-22.19%), which was numerically lower than the FNRs of SLNB alone and US combined with SLNB. HER2 status, hormone receptor status, breast pathological response after NAT, and CEUS findings were significantly associated with nodal status in the univariable GEE model. Exploratory multivariable GEE analyses identified pre-NAT HER2 positivity as an independent protective factor for false-negative LN outcomes, whereas pre-NAT ER status and residual invasive carcinoma were independently associated with CEUS-negative/SLNB-positive nodal status. The exploratory models showed high apparent discrimination, with AUCs of 0.941 (95% CI, 0.890-0.991) and 0.917 (95% CI, 0.866-0.968).
conclusionsIn this single-center retrospective cohort, the addition of post-NAT CEUS to SLNB was associated with a lower observed FNR than SLNB alone. These findings support the potential role of CEUS as a complementary tool for post-NAT axillary assessment but require prospective studies with external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.